+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H1, 2020

  • ID: 5004202
  • Clinical Trials
  • February 2020
  • Region: Global
  • 2110 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • AbbVie Inc
  • Amgen Inc
  • Bristol-Myers Squibb Co
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • MORE
Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H1, 2020

Summary

This clinical trial report, “Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H1, 2020" provides an overview of Multiple Myeloma (Kahler Disease) Clinical trials scenario. This report provides top line data relating to the clinical trials on Multiple Myeloma (Kahler Disease). The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The Clinical Trial Reports are generated using the publisher's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. The clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Scope
  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
Reasons to buy
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AbbVie Inc
  • Amgen Inc
  • Bristol-Myers Squibb Co
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • MORE
  • Report Guidance
  • Clinical Trials Report Coverage
  • Clinical Trials by Region
  • Clinical Trials and Average Enrollment by Country
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
  • Top Five Countries Contributing to Clinical Trials in Europe
  • Top Countries Contributing to Clinical Trials in North America
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
  • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
  • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
  • Top Companies Participating in Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials
  • Prominent Drugs
  • Latest Clinical Trials News on Multiple Myeloma (Kahler Disease)
  • Nov 15, 2019: OncoTherapy Science: Publication of a paper describing the anti-cancer effect of TOPK inhibitor OTS514 on multiple myeloma
  • Nov 15, 2019: Gracell announces presentations on GC-012 at the Annual Meeting of American Society of Hematology (ASH)
  • Nov 14, 2019: Prescient Therapeutics announces first patient dosed in phase 1b clinical trial for first-in-class cancer therapy PTX-100
  • Nov 08, 2019: Takeda's Ninlaro meets primary endpoint in multiple myeloma
  • Nov 07, 2019: Surface Oncology presents update on SRF231 (targeting CD47) at the Society for Immunotherapy of Cancer's Annual Meeting
  • Nov 07, 2019: Oncolytics Biotech announces abstract published for the 61st Annual Meeting & Exposition of the American Society of Hematology
  • Nov 06, 2019: Kleo Pharmaceuticals presents preclinical data supporting development of its CD38-ARM, a novel immuno-therapeutic, at American Society of Hematology (ASH) Annual Meeting
  • Nov 06, 2019: Gamida Cell announces data to be presented at ASH 2019 Annual Meeting
  • Nov 06, 2019: Allogene Therapeutics to present abstract on ALLO-715 (anti-BCMA) at 61st American Society of Hematology Annual Meeting
  • Nov 06, 2019: Stemline Therapeutics announces three ELZONRIS presentations, including an oral presentation in myelofibrosis, at Upcoming ASH Meeting
  • Nov 06, 2019: Oncopeptides to highlight data from Melflufen clinical program in Multiple Myeloma and AL Amyloidosis in six presentations at ASH Annual Meeting 2019
  • Nov 06, 2019: CALQUENCE data to show improved progression-free survival in phase III front-line Chronic Lymphocytic Leukemia At ASH 2019 Annual Meeting
  • Nov 06, 2019: Genmab to present abstracts on Daratumumab at 2019 ASH Annual Meeting
  • Nov 06, 2019: Roche to present on venetoclax at the American Society of Hematology 2019 Annual Meeting
  • Nov 06, 2019: Janssen to Present data on DARZALEX (daratumumab) at this Year's American Society of Hematology Annual Meeting
  • Nov 06, 2019: Fate Therapeutics presents poster on FT538 at the 2019 ASH Annual Meeting
  • Nov 06, 2019: Celularity to present new data at the ASH Annual Meeting on novel allogeneic, off the shelf, placental derived CAR T and NK cell therapy programs
  • Clinical Trial Profile Snapshots
  • Appendix
  • Abbreviations
  • Definitions
  • Research Methodology
  • Secondary Research
  • About the Publisher
  • Contact Us
  • Disclaimer
  • Source
List of Tables
  • Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Region, 2020*
  • Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2020*
  • Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2020*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2020*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Europe, Top Five Countries, 2020*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, North America, Top Countries, 2020*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2020*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2020*
  • Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials, G7 Countries (%), 2020*
  • Multiple Myeloma (Kahler Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2020*
  • Multiple Myeloma (Kahler Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2020*
  • Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials, E7 Countries (%), 2020*
  • Multiple Myeloma (Kahler Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2020*
  • Multiple Myeloma (Kahler Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2020*
  • Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Phase, 2020*
  • Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials In Progress by Phase 2020*
  • Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2020*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2020*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2015-2019
  • Multiple Myeloma (Kahler Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2020*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2020*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2020*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2020*
List of Figures
  • Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Region (%), 2020*
  • Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2020*
  • Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2020*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2020*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2020*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, North America, Top Countries (%), 2020*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2020*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2020*
  • Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials, G7 Countries (%), 2020*
  • Multiple Myeloma (Kahler Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2020*
  • Multiple Myeloma (Kahler Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2020*
  • Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials, E7 Countries (%), 2020*
  • Multiple Myeloma (Kahler Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2020*
  • Multiple Myeloma (Kahler Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2020*
  • Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Phase (%), 2020*
  • Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials In Progress by Phase, 2020*
  • Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2020*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2020*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018
  • Multiple Myeloma (Kahler Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2020*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2020*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2020*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2020*
  • Report Methodology
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Bristol-Myers Squibb Co
  • Johnson & Johnson
  • Takeda Pharmaceutical Co Ltd
  • Amgen Inc
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Sanofi
  • AbbVie Inc
  • Merck & Co Inc
  • GlaxoSmithKline Plc
Note: Product cover images may vary from those shown
Adroll
adroll